GENE ONLINE|News &
Opinion
Blog

2021-09-03| Asia-PacificIPO

Singapore Exchange to Allow SPAC Listings on the Mainboard

by Tyler Chen
Share To

Singapore Exchange (SGX) announced it will allow Special Purpose Acquisition Companies (SPACs) to list on the Mainboard, starting from September 3.

 

SPACs Provide Alternative Route to Listing

SPACs are a rising trend in the biotech industry. These companies would first go through the process of initial public offering (IPO) and gain funding with the sole purpose of acquiring a private company within a 2-year time limit. If SPACs failed to make it, fundings would be returned to investors.

The great thing about SPACs is that they provide a different way to go public and raise capital, and investors can have the chance to invest in promising private firms. A firm that merges with a SPAC takes its place on the listing, meaning it could go public without filing lengthy paperwork for a traditional IPO.

“SGX’s SPAC framework will give companies an alternative capital fundraising route with greater certainty on price and execution. We want the SPAC process to result in good target companies listed on SGX, providing investors with more choice and opportunities,” said Tan Boon Gin, CEO of Singapore Exchange Regulation.

Related Article: Is the Path to Public Market Smooth? A Candid Discussion on SPACs

 

SGX’s Criteria for SPACs

SPACs would have to meet certain criteria to be listed on the SGX. For starters, their market capitalization should be over $1.11 million (150 million Singapore dollars). Then, SPACs have to complete the acquisition of a private firm in 24 months with an extension of up to 12 months, which is subject to the fulfillment of prescribed conditions.

What’s more, sponsors must subscribe to at least 2.5% to 3.5% of the IPO shares depending on the market capitalization of the SPAC, and so on.

Currently, the U.S. is the biggest battlefield for SPACs. It has drawn around 420 SPACs in the first 8 months of 2021. In Asia, South Korea and Malaysia have already allowed SPACs listing, but they allow 36 months for SPACs to finish acquisition compared to the 24-month rule in the US.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
AbbVie Boosts Global Manufacturing with $223 Million Expansion in Singapore
2024-01-29
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
Singapore’s NUS Medicine Launches Centre for Sustainable Medicine
2023-11-20
LATEST
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top